# FDA Approves MannKind's Furoscix ReadyFlow Auto-Injector for Heart Failure Fluid Overload

> fda · REPORTED · 2026-07-23

The FDA approved MannKind's Furoscix ReadyFlow on July 23, 2026, an auto-injector delivering an 80mg dose of subcutaneous furosemide in 5-10 seconds for management of fluid overload in heart failure and chronic kidney disease patients. The approval triggered a $45 million contingent value rights payment, funded by a concurrent $50 million private placement led by Frazier Life Sciences.

About MannKind Corporation: MannKind Corporation is a specialty pharmaceutical company focused on pulmonary and cardiometabolic diseases, with Furoscix providing at-home subcutaneous diuretic therapy for heart failure patients.

- Company: MannKind Corporation
- Sector: medical devices
- Primary source: https://www.marketbeat.com/instant-alerts/mannkind-wins-fda-approval-for-furoscix-readyflow-secures-50m-pipe-2026-07-24/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.